Physician profile
Nancy E Pecen
NPI 1558314583
$7,407.72
in general payments reported to CMS, 2019-2025
27 companies · $1,072 in 2025
The $1,072 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,196 · 2020: $428 · 2021: $880 · 2022: $1,220 · 2023: $1,349 · 2024: $1,263 · 2025: $1,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,857.43 | 2021-2025 | |
| Corium, LLC | $1,130.68 | 2021-2025 | Azstarys |
| Lundbeck LLC | $617.61 | 2019-2025 | Rexulti |
| Allergan, INC. | $565.51 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $445.92 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $435.66 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $410.27 | 2019-2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $351.00 | 2021-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $311.59 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $167.27 | 2020-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $158.82 | 2025 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $149.45 | 2019-2025 | Fanapt |
| Axsome Therapeutics, INC. | $129.53 | 2024-2025 | Auvelity |
| Alkermes, INC. | $110.11 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $101.50 | 2019-2023 | Spravato |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $78.80 | 2019 | |
| Neurocrine Biosciences, INC. | $71.62 | 2022-2025 | Ingrezza |
| Neos Therapeutics, LP | $66.36 | 2019-2025 | Cotempla Xr-Odt |
| Almatica Pharma LLC | $53.16 | 2024 | Loreev Xr |
| Bausch Health US, LLC | $43.21 | 2022 | |
| Adlon Therapeutics L.P. | $36.27 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $24.09 | 2021 | |
| Vertical Pharmaceuticals, LLC | $23.90 | 2019-2020 | |
| Noven Therapeutics, LLC | $19.42 | 2024 | Xelstrym |
| Sunovion Pharmaceuticals INC. | $16.75 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.56 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.23 | 2024 | Austedo Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Pecen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.